Updates are available Correction dated 2018-09-03
Click to view Correction: https://doi.org/10.1038/s41551-018-0299-6
-
Authors
Golder, Matthew R. https://orcid.org/0000-0001-5848-7366
Liu, Jenny
Andersen, Jannik N.
Shipitsin, Michail V.
Vohidov, Farrukh
Nguyen, Hung V.-T.
Ehrlich, Deborah C.
Huh, Sung Jin
Vangamudi, Bhavatarini
Economides, Kyriakos D.
Neenan, Allison M.
Ackley, James C.
Baddour, Joelle
Paramasivan, Sattanathan
Brady, Samantha W.
Held, Eric J.
Reiter, Lawrence A.
Saucier-Sawyer, Jennifer K.
Kopesky, Paul W.
Chickering, Donald E.
Blume-Jensen, Peter
Johnson, Jeremiah A. https://orcid.org/0000-0001-9157-6491
- License Information
-
More Information
Article History
Received: 14 February 2018
Accepted: 19 July 2018
First Online: 20 August 2018
Change Date: 3 September 2018
Change Type: Correction
Change Details: In the version of this Article originally published, the author Peter Blume-Jensen was not denoted as a corresponding author; this has now been amended and the author’s email address has been added. The ‘Correspondence and requests for materials’ statement was similarly affected and has now been updated with the author’s initials ‘P.B-J.’
Competing interests
: J.L., J.N.A., M.V.S., S.J.H., B.V., K.D.E., A.M.N., J.C.A., J.B., S.P., S.W.B., E.J.H., J.K.S.-S., P.W.K., D.E.C. and P.B.-J. are former employees and shareholders of XTuit Pharmaceuticals. P.B.-J. is President and Founder of Acrivon Therapeutics. J.A.J. is a Co-Founder of Acrivon Therapeutics.
